JP2016538328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538328A5 JP2016538328A5 JP2016545257A JP2016545257A JP2016538328A5 JP 2016538328 A5 JP2016538328 A5 JP 2016538328A5 JP 2016545257 A JP2016545257 A JP 2016545257A JP 2016545257 A JP2016545257 A JP 2016545257A JP 2016538328 A5 JP2016538328 A5 JP 2016538328A5
- Authority
- JP
- Japan
- Prior art keywords
- forskolin
- carnitine
- acetyl
- nutritional supplement
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OHCQJHSOBUTRHG-KGGHGJDLSA-N forskolin group Chemical group C(C)(=O)O[C@H]1[C@H]([C@@H]2[C@@]([C@]3(C(C[C@](O[C@]13C)(C)C=C)=O)O)([C@H](CCC2(C)C)O)C)O OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 98
- 235000015872 dietary supplement Nutrition 0.000 claims description 52
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 48
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 48
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 44
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 30
- 244000019459 Cynara cardunculus Species 0.000 claims description 27
- 235000019106 Cynara scolymus Nutrition 0.000 claims description 27
- 235000016520 artichoke thistle Nutrition 0.000 claims description 27
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 24
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 22
- 235000019158 vitamin B6 Nutrition 0.000 claims description 22
- 239000011726 vitamin B6 Substances 0.000 claims description 22
- 229940011671 vitamin b6 Drugs 0.000 claims description 22
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 16
- 229960005190 phenylalanine Drugs 0.000 claims description 12
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 9
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 9
- 235000019100 piperine Nutrition 0.000 claims description 9
- 229940075559 piperine Drugs 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 150000002215 flavonoids Chemical class 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 8
- YDDUMTOHNYZQPO-RVXRWRFUSA-N Cynarine Chemical compound O([C@@H]1C[C@@](C[C@H]([C@@H]1O)O)(OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-RVXRWRFUSA-N 0.000 claims description 7
- 229950009125 cynarine Drugs 0.000 claims description 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- YDDUMTOHNYZQPO-UHFFFAOYSA-N 1,3-bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid Natural products OC1C(O)CC(C(O)=O)(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDUMTOHNYZQPO-UHFFFAOYSA-N 0.000 claims description 5
- SITQVDJAXQSXSA-CEZRHVESSA-N Cynarin Natural products O[C@@H]1C[C@@](C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)(OC(=O)C=Cc3cccc(O)c3O)C(=O)O SITQVDJAXQSXSA-CEZRHVESSA-N 0.000 claims description 5
- HDNHBCSWFYFPAN-IRXDYDNUSA-N Mesembrenone Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(C=CC(=O)C2)[C@H]2N(C)CC1 HDNHBCSWFYFPAN-IRXDYDNUSA-N 0.000 claims description 5
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 5
- YDDUMTOHNYZQPO-BKUKFAEQSA-N cynarine Natural products O[C@H]1C[C@@](C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O YDDUMTOHNYZQPO-BKUKFAEQSA-N 0.000 claims description 5
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 5
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 5
- 235000009498 luteolin Nutrition 0.000 claims description 5
- HDNHBCSWFYFPAN-UHFFFAOYSA-N mesembrenone Natural products C1=C(OC)C(OC)=CC=C1C1(C=CC(=O)C2)C2N(C)CC1 HDNHBCSWFYFPAN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 5
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- 235000021283 resveratrol Nutrition 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 3
- 235000021508 Coleus Nutrition 0.000 claims description 3
- 244000061182 Coleus blumei Species 0.000 claims description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 3
- -1 biocanin A Chemical compound 0.000 claims description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- 229940025878 hesperidin Drugs 0.000 claims description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 3
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- 235000005875 quercetin Nutrition 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 230000001777 nootropic effect Effects 0.000 claims 21
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 8
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 8
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 8
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 7
- 230000003920 cognitive function Effects 0.000 claims 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000005414 inactive ingredient Substances 0.000 claims 2
- 229930002697 labdane diterpene Natural products 0.000 claims 2
- 229960004203 carnitine Drugs 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 4
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 244000291564 Allium cepa Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 150000003436 stilbenoids Chemical class 0.000 description 2
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 235000005273 Canna coccinea Nutrition 0.000 description 1
- 240000008555 Canna flaccida Species 0.000 description 1
- 235000003198 Cynara Nutrition 0.000 description 1
- 241000208947 Cynara Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000002913 Trifolium pratense Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883433P | 2013-09-27 | 2013-09-27 | |
| US61/883,433 | 2013-09-27 | ||
| US201462046953P | 2014-09-06 | 2014-09-06 | |
| US62/046,953 | 2014-09-06 | ||
| US201462047055P | 2014-09-07 | 2014-09-07 | |
| US62/047,055 | 2014-09-07 | ||
| PCT/US2014/057923 WO2015048590A1 (en) | 2013-09-27 | 2014-09-27 | Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538328A JP2016538328A (ja) | 2016-12-08 |
| JP2016538328A5 true JP2016538328A5 (cg-RX-API-DMAC7.html) | 2018-09-13 |
Family
ID=52740399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545257A Pending JP2016538328A (ja) | 2013-09-27 | 2014-09-27 | Ｐｄｅ４阻害、ドーパミン代謝向上、および長期増強のための機能性食品組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9149457B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3049101A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016538328A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014324608B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2925318C (cg-RX-API-DMAC7.html) |
| IL (1) | IL244743B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015048590A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015048590A1 (en) | 2013-09-27 | 2015-04-02 | Sher Justin | Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation |
| CA3063174A1 (en) | 2017-05-12 | 2018-11-15 | Innovus Pharmaceuticals, Inc. | Therapeutic methods and compositions |
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| US20190167699A1 (en) | 2017-12-01 | 2019-06-06 | Innovus Pharmaceuticals, Inc. | Prostate function support formula |
| US10500199B2 (en) | 2017-12-01 | 2019-12-10 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for increasing cognitive functions |
| US10758505B2 (en) | 2017-12-01 | 2020-09-01 | Innovus Pharmaceuticals, Inc. | Therapeutic compositions and methods |
| US10864205B2 (en) | 2017-12-01 | 2020-12-15 | Innovus Pharmaceuticals, Inc. | Nutritional supplement for improving sexual health in men and women |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| JP7482866B2 (ja) | 2018-11-19 | 2024-05-14 | ビオラ・セラピューティクス・インコーポレイテッド | 生物学的治療薬による疾患処置方法およびデバイス |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| IT202000006094A1 (it) * | 2020-03-23 | 2021-09-23 | A M Italy S R L | Composizione per l’uso nella terapia, in particolare per la cura dell’alzheimer |
| US11999694B2 (en) | 2021-10-29 | 2024-06-04 | Sensorium Therapeutics, Inc. | Delivery of therapeutic alkaloid compounds |
| US12410128B1 (en) | 2022-04-15 | 2025-09-09 | Sensorium Therapeutics, Inc. | Therapeutic alkaloid compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
| US5925377A (en) * | 1997-08-07 | 1999-07-20 | Nova Pharmaceutical Co. | Dietary supplement composition |
| WO2000062812A1 (en) * | 1999-04-20 | 2000-10-26 | Advocare International Llc | Nutritional composition for improved cognitive performance |
| WO2006084033A1 (en) * | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| NZ543486A (en) * | 2005-11-10 | 2009-03-31 | Fonterra Corporate Res And Dev | Compositions of CIS-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof |
| US8501581B2 (en) | 2006-03-29 | 2013-08-06 | Micron Technology, Inc. | Methods of forming semiconductor constructions |
| WO2007123699A1 (en) * | 2006-03-30 | 2007-11-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for modulating melanogenesis by using a mclr agonist |
| US20080044390A1 (en) * | 2006-08-11 | 2008-02-21 | Xiaowei Jin | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2008153426A1 (en) * | 2007-06-15 | 2008-12-18 | Sealord Group Limited | Anti-inflammatory composition and use thereof |
| US8029830B2 (en) * | 2008-04-18 | 2011-10-04 | Nuvocare Health Services Inc. | Composition and method for promoting internal health and external appearance |
| WO2009143391A2 (en) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
| US8552051B2 (en) | 2009-03-20 | 2013-10-08 | H. L. Hall & Sons Limited | Use of pharmaceutical compositions containing mesembrenone |
| WO2011003045A1 (en) | 2009-07-01 | 2011-01-06 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| FR2948566B1 (fr) * | 2009-07-30 | 2012-08-10 | Expanscience Lab | Extrait du fruit de schizandra sphenanthera et compositions cosmetiques, dermatologiques et nutraceutiques le comprenant |
| US20110064720A1 (en) * | 2009-09-16 | 2011-03-17 | Daniel Moses Amato | Dietary Supplement Compositions and Methods of Making and Using the Same |
| US8202525B2 (en) * | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| US20130034530A1 (en) * | 2011-04-29 | 2013-02-07 | David R. Fantz | Dietary Supplement Cognitive Support System |
| WO2015048590A1 (en) | 2013-09-27 | 2015-04-02 | Sher Justin | Nutraceutical compositon for pde4 inhibition, enhanced dopamine metabolism and long term potentiation |
-
2014
- 2014-09-27 WO PCT/US2014/057923 patent/WO2015048590A1/en not_active Ceased
- 2014-09-27 US US14/499,143 patent/US9149457B2/en active Active
- 2014-09-27 CA CA2925318A patent/CA2925318C/en active Active
- 2014-09-27 JP JP2016545257A patent/JP2016538328A/ja active Pending
- 2014-09-27 EP EP14847980.1A patent/EP3049101A4/en not_active Withdrawn
- 2014-09-27 AU AU2014324608A patent/AU2014324608B2/en active Active
-
2016
- 2016-03-23 IL IL244743A patent/IL244743B/en active IP Right Grant
- 2016-03-25 US US15/081,787 patent/US10058529B2/en active Active
-
2019
- 2019-02-21 US US16/281,793 patent/US20190274996A1/en not_active Abandoned
- 2019-08-21 AU AU2019219780A patent/AU2019219780A1/en not_active Abandoned
-
2020
- 2020-01-06 US US16/735,424 patent/US20200147033A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538328A5 (cg-RX-API-DMAC7.html) | ||
| AU2021266209B2 (en) | Theacrine-based supplement and method of use thereof | |
| Akbari et al. | The role of plant‐derived natural antioxidants in reduction of oxidative stress | |
| Meccariello et al. | Impact of polyphenolic-food on longevity: An elixir of life. An overview | |
| Tehranizadeh et al. | Russian olive (Elaeagnus angustifolia) as a herbal healer | |
| Karbab et al. | Anti-inflammatory, analgesic activity, and toxicity of Pituranthos scoparius stem extract: An ethnopharmacological study in rat and mouse models | |
| Darsini et al. | Antioxidant potential and amino acid analysis of underutilized tropical fruit Limonia acidissima L. | |
| JP2018530517A (ja) | 一酸化窒素レベルを急激に上昇させるための組成物および方法 | |
| Navarra | The encyclopedia of vitamins, minerals, and supplements | |
| RS57563B1 (sr) | Kompozicija za farmaceutsku, nutritivnu ili kozmetičku upotrebu na bazi flavonoida koja ima pojačano antioksidantno dejstvo | |
| Sánchez-Gloria et al. | Nutraceuticals in the treatment of pulmonary arterial hypertension | |
| Seferli et al. | Bioactives of the freshwater aquatic plants, Nelumbo nucifera and Lemna minor, for functional foods, cosmetics and pharmaceutical applications, with antioxidant, anti-inflammatory and antithrombotic health promoting properties | |
| Mehjabin et al. | Flavonoid intake and risk of toxicity in chronic metabolic disease | |
| Belcaro | Pharma-standard Supplements: Clinical Use | |
| Gargantiel et al. | Nutraceuticals as therapeutic interventions in Alzheimer's disease | |
| GR1010117B (el) | Διατροφικο συμπληρωμα για την απο του στοματος χορηγηση συνδυασμου διυδρομυρισετινης, χολινης και μιας ή περισσοτερων βιταμινων με αντιοξειδωτικη δραση, χρησιμων για τη φυσιολογικη λειτουργια του ηπατος | |
| Tanaka | Flavonoids as complementary medicine for allergic diseases: current evidence and future prospects | |
| Tejada et al. | Quercetin effects on exercise induced oxidative stress and inflammation | |
| ES2445492A1 (es) | Composiciones antioxidantes de un producto obtenido del fruto de camu camu | |
| Muñoz et al. | Those responsible for the pharmacological actions of plants are the active secondary metabolites | |
| US20240207339A1 (en) | Composition comprising a phytocomplex from pomegranate and its uses | |
| Devendran et al. | Unveiling the Secrets of Sea Buckthorn: A Comprehensive Review of Its Bioactive Compounds and Potential Therapeutic Applications | |
| ABIOYE et al. | Evaluation of Antibacterial Activity of Sunflower Seed Extract on Listeria Monocytogenes and Shigella Sonnei Associated with Food Borne-Infections | |
| Medoatinsa et al. | Antipyretic and Antianemic Activities of Three Anti-Malaria Recipes from South Benin on Wistar Rats | |
| Salazar et al. | Security and Biodisponibility of Derivatives from Medicinal Plants in Food Consumption |